Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Bullish +58

Elevance Health, Inc. (ELV) Stock Analysis: Evaluating the Healthcare Giantโ€™s Growth Potential and Market Position

Dividend AI-generated analysis

๐Ÿ“ˆ Elevance Health trades at $428.26 near its 52-week high with a forward P/E of 14.47 and an average analyst target price of $451.71 suggesting 5.48% upside.

๐Ÿ’ฐ The company reported EPS of $22.59, a return on equity of 11.13%, and free cash flow exceeding $4.3 billion to support operations and dividends.

๐Ÿ“Š Revenue growth of 1.40% reflects steady expansion across health benefits, pharmacy services through CarelonRx, and broader healthcare-related services.

๐Ÿ‘ Analyst sentiment is positive with 14 Buy ratings and 8 Hold ratings against no Sell ratings, affirming confidence in strategic execution.

๐Ÿ“‰ Technical indicators show the stock above 50-day ($403.84) and 200-day ($369.22) moving averages with an RSI of 17.11 suggesting oversold territory.

๐Ÿข Elevance Health, formerly Anthem Inc., operates through four key segments serving individual, employer, and government clients including Medicare and Medicaid.

๐Ÿ’ต The company offers a dividend yield of 1.61% with a payout ratio of 30.37%, balancing shareholder rewards with retained earnings for growth.

๐Ÿ›ก๏ธ Strategic positioning includes specialty insurance products and advanced healthcare solutions leveraging the Anthem Blue Cross, Blue Shield, Wellpoint, and Carelon brands.

Bullish Signals
  • Elevance Health trades near its 52-week high of $428.43 with a forward P/E of 14.47, indicating strong investor confidence and moderate valuation relative to peers.
  • The company boasts significant free cash flow of over $4.3 billion, providing substantial flexibility to fund operations, pay dividends, and reinvest in growth opportunities.
  • Analyst sentiment is predominantly positive with 14 Buy ratings and no Sell ratings, affirming confidence in the company's strategic direction and execution capabilities.
  • The stock is positioned above both its 50-day and 200-day moving averages, indicating sustained upward momentum and technical strength.
  • Elevance Health offers a dividend yield of 1.61% with a payout ratio of 30.37%, ensuring a balanced approach between rewarding shareholders and retaining earnings.
Full Analysis
Elevance Health, Inc. (NYSE: ELV) is a major healthcare plan provider with a market capitalization of $92.88 billion and a stock price of $428.26, trading near its 52-week high. The company demonstrates strong financial stability with an earnings per share of $22.59, a return on equity of 11.13%, and significant free cash flow exceeding $4.3 billion. These metrics highlight efficient capital management and the ability to fund operations while rewarding shareholders through dividends. The firm reported revenue growth of 1.40% and maintains a forward P/E ratio of 14.47, suggesting a moderate valuation relative to peers with an average analyst target price of $451.71 indicating potential upside. Analyst sentiment is predominantly positive, reflected in 14 Buy ratings versus 8 Hold ratings, with no Sell recommendations. The consensus target price range spans from $393.00 to $492.00, affirming confidence in the company's strategic direction and execution capabilities. Technically, Elevance Health is positioned above its 50-day and 200-day moving averages, signaling sustained upward momentum despite an RSI indicating oversold conditions which could present a buying opportunity. The company, formerly Anthem Inc., operates through four key segments offering health plans to individuals, employers, and government programs like Medicare and Medicaid. Its diverse portfolio includes specialty insurance, pharmacy services via CarelonRx, and advanced healthcare solutions under brands such as Anthem Blue Cross and Blue Shield.